Chemocentryx, Inc.

Amgen Inc.

Tularik Limited

Other

Pingchen Fan

Penglie Zhang

Yibin Zeng

Jay Patrick Powers

Hiroko Tanaka

Sreenivas Punna

Rebecca M Lui

Viengkham Malathong

Venkat Reddy Mali

Xi Chen

Ju Yang

Christopher W Lange

Rajinder Paul Singh

Yandong Li

Dean R Dragoli

Manmohan Reddy Leleti

Antoni Krasinski

Jeffrey Thomas Mihalic

Xiaoqi Chen

Juan Carlos Jaen

Leping Li

Kevin Lloyd Greenman

Jeffrey P McMahon

Lianfa Li

Darren J McMurtrie

Jaroslaw Kalisiak

Dustin L McMinn

Junfa Fan

Chao Yu

Kang Dai

Ryan J Scamp

Lawrence R McGee

Valentino J Stella

Rajiv Sharma

Xiaodong Wang

John Eksterowicz

Richard V Connors

Kexue Li

Zhihong Li

Jiasheng Fu

Shichang Miao

Benjamin Fisher

Serena T Cutler

Yang Song

Daqing Sun

Xuelei Yan

Yosup Rew

Marc Labelle

Xiao He

Jeffrey Deignan

Mike Elias Lizarzaburu

Makoto Kakutani

Hiroyuki Goto

Mark M Gleason

Howard S Roth

Jeffrey P McMAHON

Stephen Joseph Shuttleworth

Darren J McMURTRIE

Ying Fu

Shugui Huang

Dai Kang

Jeffrey P Mcmahon

Yangdong Li

Manmahon Reddy Leleti

Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

Azetidinyl-acetamides as CXCR7 inhibitors

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, A, Z, Xand n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases

The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors

Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.

2-oxindole compounds

Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.

Processes and intermediates in the preparation of C5aR antagonists

Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Deuterated compounds as immunomodulators

6-5 fused rings as C5a inhibitors

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

Diazole lactams

Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases

The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications. 

Prodrugs of fused-bicyclic C5aR antagonists

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, R, R, R, R, Rand the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Compounds for treatment of PD-L1 diseases

Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors

5-5 fused rings as C5a inhibitors

Growing community of inventors

Fremont, CA, United States of America

Pingchen Fan